CN101851238B - 取代的8-杂芳基黄嘌呤 - Google Patents
取代的8-杂芳基黄嘌呤 Download PDFInfo
- Publication number
- CN101851238B CN101851238B CN2010101556967A CN201010155696A CN101851238B CN 101851238 B CN101851238 B CN 101851238B CN 2010101556967 A CN2010101556967 A CN 2010101556967A CN 201010155696 A CN201010155696 A CN 201010155696A CN 101851238 B CN101851238 B CN 101851238B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- pyridyl
- methyl
- xanthine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C1CC*CC1 Chemical compound C1CC*CC1 0.000 description 16
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
1) | 1,3-二丙基-8-(6-氯-3-吡啶基)黄嘌呤; |
2) | 1-丙基-3-炔丙基-8-(6-氯-3-吡啶基)黄嘌呤; |
3) | 1,3-二丙基-8-(6-乙基氨基-3-吡啶基)黄嘌呤; |
4) | 1,3-二丙基-8-[6-(2-羟乙基)氨基-3-吡啶基]黄嘌呤; |
呤; | |
30) | 1,3-二丙基-8-[6-(3-戊基氨基)-3-吡啶基]黄嘌呤; |
31) | 1,3-二丙基-8-[6-(2,2-二苯基乙基氨基)-3-吡啶基]黄嘌呤; |
32) | 1,3-二丙基-8-{6-[2-(1-乙基吡咯烷-1-基甲基氨基)]-3-吡啶基}黄嘌呤; |
33) | 1,3-二丙基-8-[6-(3-甲氧基苄基氨基)-3-吡啶基]黄嘌呤; |
34) | 1,3-二丙基-8-{6-[(N-苯基氨基甲酰基)甲基氨基]-3-吡啶基}黄嘌呤; |
35) | 1,3-二丙基-8-[6-(糠基氨基)-3-吡啶基]黄嘌呤; |
36) | 1,3-二丙基-8-{6-[2-(4-甲氧基苯基)乙基氨基]-3-吡啶基}黄嘌呤; |
37) | 1,3-二丙基-8-[6-(2-甲氧基苄基氨基)-3-吡啶基]黄嘌呤; |
38) | 1,3-二丙基-8-[6-(丙基氨基)-3-吡啶基]黄嘌呤; |
39) | 1,3-二丙基-8-[6-(环戊基氨基)-3-吡啶基]黄嘌呤; |
40) | 1,3-二丙基-8-[6-(环己基氨基)-3-吡啶基]黄嘌呤; |
41) | 1,3-二丙基-7-乙基-8-(6-氯-3-吡啶基)黄嘌呤; |
42) | 1,3-二丙基-7-(3-氟代丙基)-8-(6-氯-3-吡啶基)黄嘌呤; |
43) | 1,3-二丙基-7-甲基-8-(6-氯-3-吡啶基)黄嘌呤; |
44) | 1,3-二丙基-7-(2-溴代乙基)-8-(6-氯-3-吡啶基)黄嘌呤; |
45) | 1,3-二丙基-8-[6-(2-噻吩甲基氨基)-3-吡啶基]黄嘌呤; |
46) | 1,3-二丙基-8-{6-[N-(4-甲氧基苯基氨基甲酰基)甲基氨基]-3-吡啶基}黄嘌呤; |
47) | 1,3-二丙基-8-[6-(N-烟酰基甲基氨基)-3-吡啶基]黄嘌呤; |
48) | 1,3-二丙基-8-{6-[N-(4-氟代苯基氨基甲酰基)甲基氨基]-3-吡啶基)黄嘌呤; |
49) | 1,3-二丙基-8-[6-(N-异烟酰基甲基氨基)-3-吡啶基]黄嘌呤; |
50) | 1,3-二丙基-8-[6-(N-甲氧基羰基甲基氨基)-3-吡啶基]黄嘌呤; |
51) | 1,3-二丙基-8-{6-[N-苯基氨基甲酰基-N-(2-苯基氨基甲酰基氧基 |
75) | 1,3-二乙基-8-[6-(3-甲氧基苄基氨基)-3-吡啶基]黄嘌呤; |
76) | 1,3-二丙基-8-{6-[2-(3-吡啶基)-乙基氨基]-3-吡啶基}黄嘌呤; |
77) | 1,3-二乙基-8-{6-[2-(3-吡啶基)-乙基氨基]-3-吡啶基}黄嘌呤; |
78) | 1,3-二丙基-8-{6-[2-(2-吡啶基)-乙基氨基]-3-吡啶基}黄嘌呤; |
79) | 1,3-二乙基-8-{6-[2-(2-吡啶基)-乙基氨基]-3-吡啶基}黄嘌呤; |
80) | 1,3-二乙基-8-(6-吡咯烷基吡啶-3-基)黄嘌呤; |
81) | 1,3-二乙基-8-{6-[2-(1-吡咯烷基)-乙基氨基]-3-吡啶基}黄嘌呤; |
82) | 1,3-二丙基-8-[6-(2-甲氧基乙基)氨基-3-吡啶基]黄嘌呤; |
83) | 1,3-二丙基-8-[6-(2-乙酰基氨基乙基)氨基-3-吡啶基]黄嘌呤; |
84) | 1,3-二乙基-8-(6-溴-3-吡啶基)黄嘌呤; |
85) | 1,3-二丙基-8-{6-[4-(2-吡啶基)-哌嗪-1-基]-3-吡啶基}黄嘌呤; |
86) | 1,3-二乙基-8-{6-[4-(2-吡啶基)-哌嗪-1-基]-3-吡啶基}黄嘌呤; |
87) | 1,3-二乙基-8-[6-(反式-2,5-二甲基哌嗪-1-基)-3-吡啶基]黄嘌呤; |
88) | 1,3-二丙基-8-{6-[4-(2-嘧啶基)-哌嗪-1-基]-3-吡啶基}黄嘌呤; |
89) | 1,3-二乙基-8-{6-[4-(2-嘧啶基)-哌嗪-1-基]-3-吡啶基}黄嘌呤; |
90) | 1,3-二乙基-8-[6-(2-甲氧基乙基)氨基-3-吡啶基]黄嘌呤; |
91) | 1-炔丙基-3-甲基-8-(6-溴-3-吡啶基)黄嘌呤; |
92) | 1,3-二乙基-8-{6-[N-烟酰基-N-(2-甲氧基乙基)氨基]-3-吡啶基}黄嘌呤; |
93) | 1-炔丙基-3-甲基-8-[6-(2-甲氧基乙基)-3-吡啶基]黄嘌呤; |
94) | 1,3-二乙基-8-{6-[N-异烟酰基-N-(2-甲氧基乙基)氨基]-3-吡啶基}黄嘌呤; |
95) | 1-[5-(1,3-二乙基-2,3,6,7-四氢-2,6-二氧代-1H-嘌呤-8-基)吡啶-2-基]-1-(2-甲氧基乙基)-3-(吡啶-4-基)脲; |
96) | 1,3-二甲基-8-(6-溴-3-吡啶基)黄嘌呤; |
97) | 1,3-二甲基-8-(6-甲基氨基-3-吡啶基)黄嘌呤; |
98) | 1,3-二甲基-8-[6-(N-烟酰基甲基氨基)-3-吡啶基]黄嘌呤; |
99) | 1,3-二丙基-8-{6-[N-烟酰基-N-(2-甲氧基乙基)氨基]-3-吡啶基}黄嘌呤; |
100) | 1-炔丙基-3-甲基-8-{6-[N-烟酰基-N-(2-甲氧基乙基)氨基]-3-吡啶基}黄嘌呤; |
101) | 1-炔丙基-3-甲基-8-[6-(N-烟酰基甲基氨基)-3-吡啶基]黄嘌呤; |
102) | 1,3-二丙基-8-(2,6-二氯-3-吡啶基)黄嘌呤; |
103) | 1,3-二丙基-8-(2,6-二甲基氨基-3-吡啶基)黄嘌呤; |
104) | 1,3-二丙基-8-[2,6-二(2-甲氧基乙基)-3-吡啶基]黄嘌呤; |
105) | 1,3-二丙基-8-[2,6-二(N-烟酰基甲基氨基)-3-吡啶基]黄嘌呤; |
106) | 1,3-二丙基-8-[2,6-二(N-烟酰基-N-甲氧基乙基)-3-吡啶基]黄嘌呤; |
107) | 1,3-二乙基-8-{6-[N-(2-吡嗪羰基)甲基氨基]-3-吡啶基}黄嘌呤; |
108) | 1,3-二乙基-8-{6-[N-(异噁唑-5-羰基)甲基氨基]-3-吡啶基}黄嘌呤; |
109) | 1,3-二丙基-8-{6-[N-(2-吡嗪羰基)甲基氨基]-3-吡啶基}黄嘌呤; |
110) | 1,3-二丙基-8-{6-[N-(异噁唑-5-羰基)甲基氨基]-3-吡啶基}黄嘌呤; |
111) | 1,3-二丙基-8-{6-[N-(5-甲基异噁唑-3-基-3-羰基)甲基氨基]-3-吡啶基}黄嘌呤; |
112) | 1,3-二丙基-8-{6-[N-(2-氯-6-甲氧基吡啶基-4-羰基)-N-甲基氨基]-3-吡啶基}黄嘌呤; |
113) | 1,3-二丙基-8-{6-[N-(异烟酰基N-氧化物)-N-甲基氨基]-3-吡啶基}黄嘌呤; |
114) | 1-丙基-3-(4-甲氧基苯基)乙基-8-(6-甲基氨基-3-吡啶基)黄嘌呤; |
115) | 1,3-二乙基-8-{6-[N-(异烟酰基N-氧化物)-N-甲基氨基]-3-吡啶基}黄嘌呤; |
116) | 1,3-二烯丙基-8-(6-氯-3-吡啶基)黄嘌呤; |
117) | 1-丙基-3-(4-甲氧基苯基)乙基-8-[6-(N-烟酰基甲基氨基)-3-吡啶 |
基]黄嘌呤; | |
118) | 1-丙基-3-(4-甲氧基苯基)乙基-8-{6-[N-(6-氯代烟酰基)甲基氨基]-3-吡啶基}黄嘌呤; |
119) | 1,3-二烯丙基-8-[6-(N-烟酰基甲基氨基)-3-吡啶基]黄嘌呤; |
120) | 1,3-二烯丙基-8-{6-[N-(6-氯代烟酰基)甲基氨基]-3-吡啶基}黄嘌呤; |
121) | 1,3-二丙基-8-[6-(N-[6-(三氟代甲基)烟酰基]甲基氨基)-3-吡啶基]黄嘌呤; |
122) | 1,3-二乙基-8-[6-(2-羟基-5-甲基)亚苯甲基肼基(dehdehydrazono)]-3-吡啶基]黄嘌呤; |
123) | 1-环丙基-3-丙基-8-{6-[N-(6-三氟甲基烟酰基)甲基氨基]-3-吡啶基}黄嘌呤 |
124) | 1,3-二乙基-8-[6-(溴代吡啶-3-亚甲肼基(carbadehydehydrazono))-3-吡啶基]黄嘌呤; |
125) | 1-环丙基-3-乙基-8-(6-甲基氨基-3-吡啶基)黄嘌呤; |
126) | 1-环丙基-3-丙基-8-(6-甲基氨基-3-吡啶基)黄嘌呤; |
127) | 1-丙基-3-环丙基-8-(6-甲基氨基-3-吡啶基)黄嘌呤; |
128) | 1-环丙基-3-丙基-8-[6-(2-甲氧基乙基)氨基-3-吡啶基]黄嘌呤; |
129) | 1-环丙基-3-丙基-8-[6-[N-烟酰基甲基氨基)-3-吡啶基]黄嘌呤; |
130) | 1,3-二乙基-8-{6-[N-(6-氯代烟酰基)甲基氨基]-3-吡啶基}黄嘌呤; |
131) | 1,3-二丙基-8-(2-氯-6-甲氧基乙基氨基-4-吡啶基)黄嘌呤; |
132) | 1,3-二丙基-8-(2-氯-6-甲基氨基-4-吡啶基)黄嘌呤; |
133) | 1,3-二丙基-8-{2-[N-烟酰基-N-(2-甲氧基乙基)氨基]-6-氯-4-吡啶基}黄嘌呤; |
134) | 1,3-二丙基-8-[2-(N-烟酰基-N-甲基氨基)-6-氯-4-吡啶基]黄嘌呤; |
135) | 1-环丙基-3-丙基-8-{6-[N-(6-氯代烟酰基)甲基氨基]-3-吡啶基}黄嘌呤; |
136) | 1-乙基-3-环丙基-8-(6-甲基氨基-3-吡啶基)黄嘌呤; |
137) | 1-乙基-3-环丙基-8-[6-(2-甲氧基乙基)氨基-3-吡啶基]黄嘌呤; |
138) | 1,3-二乙基-8-(6-肼基-3-吡啶基)黄嘌呤; |
139) | 1,3-二乙基-8-[6-(环丙基氨基)-3-吡啶基]黄嘌呤; |
140) | 1,3-二乙基-8-[6-(环丙基甲基氨基)-3-吡啶基]黄嘌呤; |
141) | N’-[5-(1,3-二乙基-2,6-二氧代-2,3,6,7-四氢-1H-嘌呤-8-基)-吡啶-2-基]-酰肼; |
142) | N-[5-(1,3-二乙基-2,6-二氧代-2,3,6,7-四氢-1H-嘌呤-8-基)-吡啶-2-基]-N’-(吡啶-3-羰基)-酰肼; |
143) | 1,3-二乙基-8-[6-(乙基氨基)-3-吡啶基]黄嘌呤; |
144) | 1,3-二乙基-8-[6-(N-烟酰基环丙基甲基氨基)-3-吡啶基]黄嘌呤;和 |
145) | 1-环丙基甲基-3-乙基-8-{6-[N-(6-氯代烟酰基)甲基氨基]-3-吡啶基}黄嘌呤。 |
Claims (28)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49787503P | 2003-08-25 | 2003-08-25 | |
US60/497875 | 2003-08-25 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2004800314554A Division CN1894250B (zh) | 2003-08-25 | 2004-08-20 | 取代的8-杂芳基黄嘌呤 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101851238A CN101851238A (zh) | 2010-10-06 |
CN101851238B true CN101851238B (zh) | 2012-07-18 |
Family
ID=34272616
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010101556967A Active CN101851238B (zh) | 2003-08-25 | 2004-08-20 | 取代的8-杂芳基黄嘌呤 |
CN2004800314554A Active CN1894250B (zh) | 2003-08-25 | 2004-08-20 | 取代的8-杂芳基黄嘌呤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2004800314554A Active CN1894250B (zh) | 2003-08-25 | 2004-08-20 | 取代的8-杂芳基黄嘌呤 |
Country Status (20)
Country | Link |
---|---|
US (3) | US7342006B2 (zh) |
EP (2) | EP2295434B1 (zh) |
JP (1) | JP4769721B2 (zh) |
KR (1) | KR101222364B1 (zh) |
CN (2) | CN101851238B (zh) |
AR (1) | AR045499A1 (zh) |
AU (1) | AU2004268964B2 (zh) |
BR (1) | BRPI0413922B8 (zh) |
CA (1) | CA2536553C (zh) |
DK (2) | DK1658291T3 (zh) |
ES (2) | ES2440467T3 (zh) |
HK (2) | HK1096397A1 (zh) |
IL (1) | IL173723A (zh) |
NZ (1) | NZ545715A (zh) |
PL (1) | PL1658291T3 (zh) |
PT (1) | PT1658291E (zh) |
RU (1) | RU2357969C2 (zh) |
TW (1) | TWI362390B (zh) |
WO (1) | WO2005021548A2 (zh) |
ZA (1) | ZA200602333B (zh) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003029264A2 (en) * | 2001-10-01 | 2003-04-10 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US7205403B2 (en) * | 2002-02-01 | 2007-04-17 | King Pharmaceuticals Research And Development, Inc. | 8-Heteroaryl xanthine adenosine A2B receptor antagonists |
US7342006B2 (en) * | 2003-08-25 | 2008-03-11 | Adenosine Therapeutics, Llc | Substituted 8-heteroaryl xanthines |
AU2005267706B2 (en) * | 2004-08-02 | 2011-12-08 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity |
CN101083982A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物 |
WO2006034441A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
JP4958786B2 (ja) * | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
AU2005329423A1 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
TW200626138A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
CN101083992A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物 |
WO2006034446A2 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridine derivatives for inhibiting human stearoyl-coa-desaturase |
AR051091A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
US7618962B2 (en) * | 2005-02-25 | 2009-11-17 | Pgx Health, Llc | Pyrazolyl substituted xanthines |
US7598379B2 (en) | 2005-02-25 | 2009-10-06 | Pgx Health, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
WO2006091897A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Derivatives of 8-substituted xanthines |
GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
MX2007015216A (es) | 2005-06-03 | 2008-02-22 | Xenon Pharmaceuticals Inc | Derivados de aminotiazol y sus usos como agentes terapeuticos. |
RU2415858C2 (ru) * | 2005-06-16 | 2011-04-10 | Си Ви Терапьютикс, Инк. | Пролекарства антагонистов a2b рецептора аденозина |
ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
EP1923388A4 (en) | 2005-08-12 | 2011-03-09 | Takeda Pharmaceutical | BRAIN / NERVE CELL PROTECTION AND THERAPEUTIC FOR SLEEP DISORDERS |
US20070059740A1 (en) * | 2005-08-26 | 2007-03-15 | Linden Joel M | Method of targeting a2b adenosine receptor antagonist therapy |
US7566401B2 (en) * | 2005-10-03 | 2009-07-28 | Kelm Mark A | Process for separating and isolating xanthines, individual polar protic monomers, and polar protic oligomers |
ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
US8178509B2 (en) * | 2006-02-10 | 2012-05-15 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
GB0606774D0 (en) * | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
US7884100B2 (en) * | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
UA105164C2 (en) | 2006-06-16 | 2014-04-25 | Догвуд Фармасьютикалз, Инк | Substituted 8-[6-amino-3-pyridyl]xanthines |
US8188063B2 (en) * | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
US8193200B2 (en) * | 2007-01-04 | 2012-06-05 | University Of Virginia Patent Foundation | Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease |
US7875608B2 (en) * | 2007-12-17 | 2011-01-25 | Thompson Robert D | Substituted 8-[6-amino-3pyridyl]xanthines |
CN102015712A (zh) | 2008-03-26 | 2011-04-13 | 阿德维纳斯治疗私人有限公司 | 作为腺苷受体拮抗剂的杂环化合物 |
JP2011528364A (ja) * | 2008-07-16 | 2011-11-17 | キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド | アテローム性動脈硬化症の治療 |
EP2405917B1 (en) | 2009-03-13 | 2014-04-23 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
WO2011005871A1 (en) * | 2009-07-07 | 2011-01-13 | Pgxhealth, Llc | Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists |
US8796290B2 (en) | 2009-11-09 | 2014-08-05 | Advinus Therapeutics Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
WO2012035548A1 (en) | 2010-09-13 | 2012-03-22 | Advinus Therapeutics Private Limited | Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications |
EP2465859A1 (en) * | 2010-12-08 | 2012-06-20 | Life & Brain GmbH | 8-Triazolylxanthine derivatives, processes for their production and their use as adenosine receptor antagonists |
CN102532137B (zh) * | 2011-12-05 | 2014-12-10 | 辽宁医学院 | 8-吡唑取代黄嘌呤类a2b腺苷受体拮抗剂及其合成方法和应用 |
EP3389664A4 (en) * | 2015-12-14 | 2020-01-08 | Raze Therapeutics Inc. | MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF |
US11548867B2 (en) | 2017-07-19 | 2023-01-10 | Idea Ya Biosciences, Inc. | Amido compounds as AhR modulators |
EP4126866A1 (en) * | 2020-03-26 | 2023-02-08 | Inspyr Therapeutics, Inc. | 8-substituted diaryl xanthines as dual a2a-a2b antagonists |
CN117337263A (zh) | 2021-05-18 | 2024-01-02 | 阿多维特有限责任公司 | 作为a2b拮抗剂的含环酰胺的吡啶基黄嘌呤 |
CN113262882B (zh) * | 2021-07-21 | 2021-09-17 | 北京矿冶研究总院 | 阳离子捕收剂、制备方法及在磷矿反浮选中的应用 |
WO2024050825A1 (en) * | 2022-09-09 | 2024-03-14 | National Institute Of Biological Sciences, Beijing | Compounds as mlkl inhibitors |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2443023A1 (en) * | 2002-02-01 | 2003-08-07 | King Pharmaceuticals Research And Development, Inc. | 8-heteroaryl xanthine adenosine a2b receptor antagonists |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
JPH06102662B2 (ja) * | 1989-09-01 | 1994-12-14 | 協和醗酵工業株式会社 | キサンチン誘導体 |
AU1507099A (en) * | 1997-12-15 | 1999-07-05 | Kyowa Hakko Kogyo Co. Ltd. | Preventives/remedies for sleep disturbance |
US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
US6060481A (en) | 1998-05-28 | 2000-05-09 | The Penn State Research Foundation | Method for improving insulin sensitivity using an adenosine receptor antagonist |
GB9817623D0 (en) * | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
US6545002B1 (en) | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
EP1234576B1 (en) * | 1999-10-29 | 2006-03-08 | Kyowa Hakko Kogyo Co., Ltd. | Pharmaceutical composition for eating disorders |
EP1255550A2 (en) * | 2000-02-17 | 2002-11-13 | Cv Therapeutics, Inc. | Method for identifying and using a 2b adenosine receptor antagonists to mediate mammalian cell proliferation |
JP4350517B2 (ja) | 2001-11-09 | 2009-10-21 | シーブイ・セラピューティクス・インコーポレイテッド | A2bアデノシン受容体アンタゴニスト |
US7304070B2 (en) | 2001-11-09 | 2007-12-04 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US6977300B2 (en) | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US7034070B2 (en) * | 2002-09-27 | 2006-04-25 | Vincent Chuang | Arylalkyl aminofunctional silanes for epoxy laminates |
US7148229B2 (en) | 2003-02-19 | 2006-12-12 | Hoffman-La Roche Inc. | Sulfonamide substituted xanthine derivatives |
US7342006B2 (en) | 2003-08-25 | 2008-03-11 | Adenosine Therapeutics, Llc | Substituted 8-heteroaryl xanthines |
KR101247528B1 (ko) | 2004-09-01 | 2013-04-15 | 길리애드 사이언시즈, 인코포레이티드 | A2b 아데노신 수용체 길항제를 사용하는 상처 치유 방법 |
NZ554485A (en) | 2004-10-15 | 2010-12-24 | Gilead Palo Alto Inc | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists |
US7618962B2 (en) | 2005-02-25 | 2009-11-17 | Pgx Health, Llc | Pyrazolyl substituted xanthines |
WO2006091897A2 (en) | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Derivatives of 8-substituted xanthines |
WO2006091896A2 (en) | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyridyl substituted xanthines |
US7598379B2 (en) | 2005-02-25 | 2009-10-06 | Pgx Health, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
RU2415858C2 (ru) | 2005-06-16 | 2011-04-10 | Си Ви Терапьютикс, Инк. | Пролекарства антагонистов a2b рецептора аденозина |
CA2646333C (en) * | 2006-03-17 | 2014-06-17 | Cv Therapeutics, Inc. | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
US7884100B2 (en) | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
US7767685B2 (en) | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
US7875608B2 (en) * | 2007-12-17 | 2011-01-25 | Thompson Robert D | Substituted 8-[6-amino-3pyridyl]xanthines |
CN102015712A (zh) * | 2008-03-26 | 2011-04-13 | 阿德维纳斯治疗私人有限公司 | 作为腺苷受体拮抗剂的杂环化合物 |
-
2004
- 2004-08-20 US US10/923,592 patent/US7342006B2/en active Active
- 2004-08-20 WO PCT/US2004/027133 patent/WO2005021548A2/en active Application Filing
- 2004-08-20 CN CN2010101556967A patent/CN101851238B/zh active Active
- 2004-08-20 DK DK04781752.3T patent/DK1658291T3/da active
- 2004-08-20 RU RU2006109474/04A patent/RU2357969C2/ru active
- 2004-08-20 KR KR1020067003776A patent/KR101222364B1/ko active IP Right Grant
- 2004-08-20 CN CN2004800314554A patent/CN1894250B/zh active Active
- 2004-08-20 NZ NZ545715A patent/NZ545715A/en not_active IP Right Cessation
- 2004-08-20 PT PT47817523T patent/PT1658291E/pt unknown
- 2004-08-20 JP JP2006524755A patent/JP4769721B2/ja active Active
- 2004-08-20 ES ES04781752.3T patent/ES2440467T3/es active Active
- 2004-08-20 PL PL04781752T patent/PL1658291T3/pl unknown
- 2004-08-20 AU AU2004268964A patent/AU2004268964B2/en not_active Ceased
- 2004-08-20 ES ES10012271.2T patent/ES2557310T3/es active Active
- 2004-08-20 EP EP10012271.2A patent/EP2295434B1/en active Active
- 2004-08-20 CA CA2536553A patent/CA2536553C/en active Active
- 2004-08-20 DK DK10012271.2T patent/DK2295434T3/en active
- 2004-08-20 BR BRPI0413922A patent/BRPI0413922B8/pt not_active IP Right Cessation
- 2004-08-20 EP EP04781752.3A patent/EP1658291B1/en active Active
- 2004-08-25 AR ARP040103058A patent/AR045499A1/es not_active Application Discontinuation
- 2004-08-26 TW TW093125436A patent/TWI362390B/zh active
-
2006
- 2006-02-14 IL IL173723A patent/IL173723A/en active IP Right Grant
- 2006-03-22 ZA ZA200602333A patent/ZA200602333B/en unknown
-
2007
- 2007-04-03 HK HK07103594.7A patent/HK1096397A1/xx not_active IP Right Cessation
- 2007-12-14 US US11/956,876 patent/US7732455B2/en active Active
-
2010
- 2010-04-19 US US12/762,711 patent/US20100273780A1/en not_active Abandoned
-
2011
- 2011-03-14 HK HK11102551.4A patent/HK1148518A1/xx not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2443023A1 (en) * | 2002-02-01 | 2003-08-07 | King Pharmaceuticals Research And Development, Inc. | 8-heteroaryl xanthine adenosine a2b receptor antagonists |
Non-Patent Citations (1)
Title |
---|
KUZ"MENKO.I.I et al.REACTIONS OF THEOPHYLLINES. CHEMICAL CONVERSIONS OF 8-AMINOTHEOPHYLLINATES.《Chemistry of Heterocyclic Compounds》.2000,第36卷(第8期),963-970. * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101851238B (zh) | 取代的8-杂芳基黄嘌呤 | |
US7579348B2 (en) | Derivatives of 8-substituted xanthines | |
US7601723B2 (en) | Pyridyl substituted xanthines | |
US8258142B2 (en) | Substituted 8-[6-amino-3-pyridyl]xanthines | |
US7875608B2 (en) | Substituted 8-[6-amino-3pyridyl]xanthines | |
US7470697B2 (en) | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors | |
CN101466382A (zh) | 取代的8-[6-氨基-3-吡啶基]黄嘌呤 | |
MXPA06002223A (en) | Substituted 8-heteroaryl xanthines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1148518 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1148518 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: TROVIS PHARMACEUTICALS LLC Free format text: FORMER OWNER: ZHUOWEISI PHARMACEUTICAL CO., LTD. Effective date: 20131024 Owner name: DOUG WOOD MEDICINE CORP. Free format text: FORMER OWNER: CLINICAL DATA INC. Effective date: 20131024 Owner name: FURUISITE LABORATORY HOLDING CO., LTD. Free format text: FORMER OWNER: DOUG WOOD MEDICINE CORP. Effective date: 20131024 Owner name: DOUG WOOD MEDICINE CORP. Free format text: FORMER OWNER: FURUISITE LABORATORY HOLDING CO., LTD. Effective date: 20131024 Owner name: CLINICAL DATA INC. Free format text: FORMER OWNER: TROVIS PHARMACEUTICALS LLC Effective date: 20131024 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20131024 Address after: Virginia Patentee after: Dogwood Pharmaceuticals, Inc. Address before: Bermuda Hamill Patentee before: Laboratory of Forest Holdings Ltd. Effective date of registration: 20131024 Address after: Bermuda Hamill Patentee after: Laboratory of Forest Holdings Ltd. Address before: Virginia Patentee before: Dogwood Pharmaceuticals, Inc. Effective date of registration: 20131024 Address after: Virginia Patentee after: Dogwood Pharmaceuticals, Inc. Address before: American New York Patentee before: Clinical Data Inc. Effective date of registration: 20131024 Address after: American New York Patentee after: Clinical Data Inc. Address before: American New York Patentee before: Travis Pharmaceutical Holdings Effective date of registration: 20131024 Address after: American New York Patentee after: Travis Pharmaceutical Holdings Address before: Massachusetts, USA Patentee before: Zhuowei Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20210729 Address after: New jersey, USA Patentee after: Erjian Sales Co.,Ltd. Address before: Virginia Patentee before: Dogwood Pharmaceuticals, Inc. |
|
TR01 | Transfer of patent right |